#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Breast cancer metastatic Non-small cell lung cancer metastatic Type 2 diabetes mellitus More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Sickle cell anaemia Blastic plasmacytoid dendritic cell neoplasia Pustular psoriasis Synovitis Chronic myeloid leukaemia Endometrial cancer Hyperinsulinaemic hypoglycaemia Myotonic dystrophy Cholangiosarcoma Congenital hypotransferrinaemia Cerebellar ataxia Aplastic anaemia Extranodal marginal zone B-cell lymphoma (MALT type) Fibrosarcoma Hepatobiliary cancer More trials…

    Learn about Rare Diseases

    Toxic epidermal necrolysis – Diagnostics Chondrosarcoma metastatic – Basic Information Systemic sclerosis pulmonary – Trials in Disease Factor IX deficiency – Diagnostics Sjogren’s syndrome – Diagnostics Hyperoxaluria – Trials in Disease Undifferentiated sarcoma Carcinoid syndrome – Treatment Progressive supranuclear palsy – Basic Information Pulmonary sarcoidosis – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Camonsertib Donepezil Caraway Oil Dmd06-Mab IMB 101 Deferoxamine Mesilate Pemetrexed Disodium Efavirenz Munc-Cd34 Brimonidine ISPAGHULA HUSK CHONDROITIN SULFATE SODIUM Ipilimumab F44/10 Dexamethasone Isonicotinate Degarelix Thiopental Sodium Dornase Alfa Ataluren Ulipristal Acetate More therapies…

    Learn about Your Condition

    Left ventricular dysfunction Gastrointestinal carcinoma Notalgia paraesthetica HER2 positive breast cancer Thrombolysis Bacterial infection Immunodeficiency congenital Hodgkin's disease refractory Chronic lymphocytic leukaemia Exudative retinopathy Ligament sprain Sarcoma metastatic Oesophageal food impaction Pyelonephritis acute Carotid artery occlusion More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Praglandia s.r.o.

Praglandia s.r.o.

Ndxvryxv 3abecyigk Skrzrxqa Puyneer 1mb 0vt Crmshmk

Want to learn more about this study or check if you can participate? Contact us.

  • Study of Camoteskimab and Sodium Chloride Placebo in Adults with Moderate-to-Severe Atopic Dermatitis

    Recruiting

    2 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Sodium Chloride
    Bulgaria Czechia Germany Hungary Poland Spain

  • Long‑Term Safety and Tolerability of Oral Fesoterodine in Adults with Hallucinations and Delusions Due to Alzheimer’s Disease Psychosis

    Recruiting

    2 1 1
    Investigated Drugs:
    • 5-[(1R,5R)-3-AZABICYCLO[3.1.0]HEXAN-1-YL]-3-METHYL-1,2,4-OXADIAZOLE
    Bulgaria Czechia France Hungary Italy Poland +3

  • Long-Term Safety and Efficacy of Zasocitinib in Adults with Active Psoriatic Arthritis

    Recruiting

    3 1
    Investigated Drugs:
    • Zasocitinib
    Belgium Bulgaria Croatia Czechia Estonia France +7

  • A study to evaluate the effect of orforglipron on cardiovascular health in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease

    Recruiting

    3 1
    Investigated Diseases:
    • Arteriosclerosis
    Austria Belgium Bulgaria Czechia Estonia France +10

  • Long-term safety study of deucravacitinib compared to ustekinumab in adults with moderate to severe plaque psoriasis

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Ustekinumab
    • Deucravacitinib
    Belgium Bulgaria Czechia Denmark France Germany +6

  • Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

    Recruiting

    3 1
    Investigated Drugs:
    • ZILEBESIRAN
    Austria Belgium Bulgaria Czechia Denmark France +11

  • A Study of Fesoterodine and 5-[(1R,5R)-3-Azabicyclo[3.

    Recruiting

    2 1
    Investigated Drugs:
    • 5-[(1R,5R)-3-AZABICYCLO[3.1.0]HEXAN-1-YL]-3-METHYL-1,2,4-OXADIAZOLE
    Bulgaria Czechia France Hungary Italy Poland +3

  • Safety and Tolerability Study of NBI-1065845 as Additional Treatment for Adults with Major Depressive Disorder

    Recruiting

    3 1 1
    Investigated Drugs:
    • 9-(4-CYCLOHEXYLOXYPHENYL)-7-METHYL-3,4-DIHYDROPYRAZINO[2,1-C][1,2,4]THIADIAZINE 2,2-DIOXIDE
    Belgium Bulgaria Croatia Czechia Estonia Finland +10

  • Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

    Recruiting

    3 1
    Bulgaria Czechia Denmark France Germany Greece +7

  • Study of milsaperidone as an additional treatment for adults with Major Depressive Disorder who are already taking antidepressants

    Recruiting

    3 1
    Investigated Diseases:
    • Major depression
    Investigated Drugs:
    • (1S)-1-[4-[3-[4-(6-FLUORO-1,2-BENZOXAZOL-3-YL)PIPERIDIN-1-YL]PROPOXY]-3-METHOXYPHENYL]ETHANOL
    Bulgaria Czechia Germany Poland
1 2 3 … 6
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!